Dr. Didier Raoult's peer reviewed study on 1,061 COVID-19 patients

[admin]

https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf?fbclid=IwAR2Bx-Fldm2fFsLg7L06BYUz-8QvwuJ-hAW9uWmwx1KdKzCU0YGHtSwXXWw

ABSTRACT

Background

In a recent survey, most physicians worldwide considered that hydroxychloroquine (HCQ) and azithromycin (AZ) are the two most effective drugs among available molecules against COVID-19. Nevertheless, to date, one preliminary clinical trial only has demonstrated its efficacy on the viral load. Additionally, a clinical study including 80 patients was published, and in vitro efficiency of this association was demonstrated.

Methods

The study was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the HCQ-AZ combination and a follow-up of at least 9 days was investigated. Endpoints were death, worsening and viral shedding persistence.

Findings

From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR. Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met our inclusion criteria. Their mean age was 43.6 years old and 492 were male (46.4%). No cardiac toxicity was observed. A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage at completion of treatment was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < 10-2) but viral culture was negative at day 10 and all but one were PCR-cleared at day 15. A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more. Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far). Poor clinical outcome was significantly associated to older age (OR 1.11), initial higher severity (OR 10.05) and low hydroxychloroquine serum concentration. In addition, both poor clinical and virological outcomes were associated to the use of selective beta-blocking agents and angiotensin II receptor blockers (P<0.05). Mortality was significantly lower in patients who had received >3 days of HCQ-AZ than in patients treated with other regimens both at IHU and in all Marseille public hospitals (p< 10-2).

Interpretation

The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.
____________________________________________

Since there is no reference to having zinc added, if it wasn't, this may be enough reason to imagine that his success might perhaps have been closer to Zelenko's success rate, if they were otherwise all treated immediately upon presentation of symptoms.

[admin]

Please read this at the link as there are videos and more.
https://www.independentsentinel.com/french-study-of-1k-by-famed-virologist-cures-91-7-of-cov-patients/

French study of 1K+ by famed virologist cures 91.7% of COV patients
By
M. Dowling -
April 10, 2020

It takes, usually, upwards of five years to develop a vaccine and they are often not fully effective. We still don’t have a vaccine for AIDS. What we need for coronavirus is a cure and eventually a vaccine. Since COV-19 has many of the symptoms of other cases of flu, pneumonia, and viruses, drugs that have worked in the past have the potential to work with this COVID-19 as well. A combination of hydroxychloroquine and Azithromycin are two of those drugs.
THE NEW FRENCH STUDY

Famed French microbiologist Didier Raoult released a new (not double-blind immoral) study on a combination of drugs — hydroxychloroquine and Azithromycin. The study was conducted with 1061 patients suffering from Coronavirus. Mr. Raoult does not believe in control groups with deadly diseases since it means letting one group go without help.

The new study, of which the abstract was released Thursday, was performed at IHU Méditerranée Infection, Marseille, France.

A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.

Key findings are:

    No cardiac toxicity was observed.

    A good clinical outcome and a virological cure were obtained in 973 patients within 10 days (91.7%).

A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.
The authors conclude that:

“The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiousity in most cases.”